Lifecore Biomedical, Inc. LFCR
6.42 USD +0.02 (+0.31%)
At closeNov 13, 2026, 5:25 PM EST
6.42 0.00 0.00%
After hours · Nov 13, 5:25 PM ET
6.38 Day range 6.42
3.66 52-week range 8.82
- YTD
- -21.52%
- 1 year
- -18.63%
News
globenewswire.com BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR) BALA CYNWYD, Pa., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky…
benzinga.com Lifecore Biomedical Q3 EPS $(1.08) Misses $(0.28) Estimate, Sales $25.322M Miss $26.699M Estimate Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.28) by 285.71 percent. This is a 285.71 percent decrease over…
benzinga.com Lifecore Biomedical Q2 2026 Earnings Call Transcript Lifecore Biomedical (NASDAQ:LFCR) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For…
benzinga.com Deal Dispatch: Hormel Acquires Brakebush, Onsemi buys Synaptics for $5.7 Billion, Leslie’s Pools Bankruptcy Major M&A deals include Valley National buys Bluevine, Roland Foods buys Savor Brands, Bloomberg completes Canoe deal.
benzinga.com Wynnefield Capital Discloses About 14.3% Stake In Lifecore Biomedical, Agrees To Vote In Favor Of Its Pending Merger, Per 13D Filing https://www.sec.gov/Archives/edgar/data/1005286/000110465926111939/xslSCHEDULE_13D_X02/primary_doc.xml
benzinga.com Barrington Research Downgrades Lifecore Biomedical to Market Perform Barrington Research analyst Michael Petusky downgrades Lifecore Biomedical (NASDAQ:LFCR) from Outperform to Market Perform.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Kodiak Sciences (NASDAQ:KOD) shares moved upwards by 172.3% to $88.08 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY)…
benzinga.com Lifecore Biomedical To Be Acquired By Webster Equity Partners In Up To $663.7M Transaction; Stockholders May Receive Up To $9.67 Per Common Equivalent In Combined Cash And CVR At Full Performance Milestone Payments Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a 49.5% PremiumLifecore Series A Preferred Stockholders Will Receive Required "Conversion Amount" per Share in…
benzinga.com Lifecore Biomedical Q2 EPS $(0.19) Beats $(0.22) Estimate, Sales $34.200M Beat $32.016M Estimate Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 24 percent increase over losses of…
benzinga.com Lifecore Biomedical Affirms FY2026 Sales Guidance of $120.000M-$125.000M vs $122.176M Est Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $120.000 million-$125.000 million to $120.000 million-$125.000 million vs $122.176 million estimate.- benzinga.com Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6.5 Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and raises the price target from $6 to $6.5.
benzinga.com Lifecore Biomedical Signs Manufacturing Services Agreement To Perform Process Development And Technical Transfer Services In Support Of Anticipated Commercial Manufacturing Upon Regulatory Approval -- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Injectable Ophthalmic Product ---- Sixth Addition to Late-Stage Pipeline in Seven Months --CHASKA, Minn.,…
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com Lifecore Biomedical Q1 2026 Earnings Call Transcript
benzinga.com Lifecore Biomedical Affirms FY2026 Sales Guidance of $120.000M-$125.000M vs $122.430M Est Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $120.000 million-$125.000 million to $120.000 million-$125.000 million vs $122.430 million estimate.
benzinga.com Lifecore Biomedical Q1 EPS $(0.43) Misses $(0.24) Estimate, Sales $23.193M Miss $26.501M Estimate Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.24) by 79.17 percent. This is a 18.87 percent increase over losses…- benzinga.com Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6 Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and raises the price target from $5.5 to $6.
- benzinga.com Lifecore Expands Manufacturing Deal With Existing Pharma Client Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that it has signed two CDMO…
- benzinga.com CORRECTION: Lifecore Biomedical Q4 EPS $(0.16) Up From $(0.20) YoY, Sales $35.747M Down From $37.886M YoY Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.16) per share. This is a 20 percent increase over losses of $(0.20) per share from the same period last year. The company reported…
- benzinga.com Barrington Research Upgrades Lifecore Biomedical to Outperform, Announces $5.5 Price Target Barrington Research analyst Michael Petusky upgrades Lifecore Biomedical (NASDAQ:LFCR) from Market Perform to Outperform and announces $5.5 price target.
benzinga.com Lifecore Stock Sinks As Delayed Launches Push Growth Further Out Lifecore stock plunges after earnings miss and weak 2026 outlook, with customer losses and delayed growth plans weighing on shares.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Lifecore Biomedical Sees FY2026 Sales $120.000M-$125.000M vs $129.846M Est Lifecore Biomedical (NASDAQ:LFCR) sees FY2026 sales of $120.000 million-$125.000 million vs $129.846 million analyst estimate.
- benzinga.com Earnings Scheduled For March 16, 2026
- benzinga.com Lifecore Biomedical Announces Development Services Agreement To Provide Indomo With CDMO Services To Support Continued Development Of Corticosteroid Drug Candidate, DT-001 Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered with the ClearPen™, its Proprietary Intradermal Self-Injection DeviceLifecore to Manufacture Drug…
- benzinga.com Lifecore Biomedical Lands Major Global Pharma Deal to Make Injectable Drug in the US Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has signed a CDMO master services…
- benzinga.com Lifecore Biomedical Affirms FY2026 Sales Guidance of $74.000M-$76.000M vs $131.882M Est Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $74.000 million-$76.000 million to $74.000 million-$76.000 million vs $131.882 million estimate.
- benzinga.com Lifecore Biomedical Q1 EPS $(0.29) Beats $(0.30) Estimate, Sales $31.109M Beat $26.471M Estimate Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.30) by 4.92 percent. This is a 45.28 percent increase over losses of…
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com Lifecore Expands CDMO Business, Becomes Supplier Of Choice For Leading Injectable Drug Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has signed an agreement with a leading…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Keybanc Initiates Coverage On Lifecore Biomedical with Sector Weight Rating Keybanc analyst Paul Knight initiates coverage on Lifecore Biomedical (NASDAQ:LFCR) with a Sector Weight rating.
- benzinga.com Lifecore Biomedical Sees FY2026 Sales $74.000M-$76.000M vs $127.802M Est Lifecore Biomedical (NASDAQ:LFCR) sees FY2026 sales of $74.000 million-$76.000 million vs $127.802 million analyst estimate.
- benzinga.com Lifecore Biomedical Q4 EPS $(0.06) Beats $(0.10) Estimate, Sales $36.444M Beat $35.363M Estimate Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.10) by 36.84 percent. This is a 70 percent increase over losses of…
- benzinga.com Earnings Scheduled For August 7, 2025
- benzinga.com Lifecore Signs 10-Year Deal to Make Eye Drug, Boosting Long-Term Revenue Growth Prospects Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has signed a new 10-year commercial…
- benzinga.com William Blair Initiates Coverage On Lifecore Biomedical with Outperform Rating William Blair analyst Max Smock initiates coverage on Lifecore Biomedical (NASDAQ:LFCR) with a Outperform rating.
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Lifecore Biomedical Q3 2025 GAAP EPS $(0.47) Misses $(0.15) Estimate, Sales $35.154M Beat $33.229M Estimate Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.15) by 213.33 percent. This is a 217.5 percent decrease over…
- benzinga.com Earnings Scheduled For April 3, 2025
- benzinga.com Lifecore Biomedical Announces $17M Sales Agreement For 10-Head Isolator Filler, Receives $7M At Closing, Expects Remaining Payments In 3 Tranches Over 18 Months Company Believes it is Well Positioned for Mid-Term and Long-Term Growth asCurrent Capacity Continues to Support up to $300 Million in Annual RevenueCHASKA, Minn., Jan. 07, 2025 (GLOBE NEWSWIRE) --…
- benzinga.com Stephens & Co. Reiterates Equal-Weight on Lifecore Biomedical, Maintains $6 Price Target Stephens & Co. analyst Jacob Johnson reiterates Lifecore Biomedical (NASDAQ:LFCR) with a Equal-Weight and maintains $6 price target.
benzinga.com US Stocks Poised To Open Higher As Futures Advance: Tesla, Bumble, Lifecore Bio In Focus U.S. stock futures were higher on Friday, the slipping in first trading session of 2025. All four index futures advanced in premarket trade.
benzinga.com Resources Connection, SPS Commerce And 3 Stocks To Watch Heading Into Friday US stock futures up, GeneDx appoints new COO, Lifecore beats expectations, SPS Commerce acquires Carbon6, Resources Connection & UDR report strong quarters.
benzinga.com Lifecore Biomedical Earnings Report: Q2 Overview - benzinga.com Lifecore Biomedical Q2 2025 GAAP EPS $(0.25) Beats $(0.29) Estimate, Sales $32.60M Beat $29.75M Estimate Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.29) by 13.79 percent. The company reported quarterly sales of $32.60…
benzinga.com Nio, Li Auto And 3 Stocks To Watch Heading Into Thursday - benzinga.com Earnings Scheduled For January 2, 2025
benzinga.com S&P 500 Surges 23% In 2024, But Greed Index Remains In 'Fear' Zone The CNN Money Fear & Greed index showed a slight easing in fear, while US stocks closed lower but still recorded gains in 2024.- benzinga.com Craig-Hallum Maintains Buy on Lifecore Biomedical, Raises Price Target to $10 Craig-Hallum analyst Matthew Hewitt maintains Lifecore Biomedical (NASDAQ:LFCR) with a Buy and raises the price target from $8 to $10.